Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 4.765
+0.060 (1.28%)
Nov 10, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 217 employees as of June 30, 2026. That makes Ascletis Pharma the 26,204th largest employer in the world and 1,667th in Hong Kong.
Employees
217
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
5.04K HKD
Profits / Employee
-3.15M HKD
Market Cap
5.03B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 217 | - | - |
| Dec 31, 2025 | 202 | -29 | -12.55% |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 1,925 |
| Lepu Biopharma | 646 |
| Ocumension Therapeutics | 608 |
| Alphamab Oncology | 515 |
| CARsgen Therapeutics Holdings | 424 |
| Mirxes Holding Company | 347 |
| Abbisko Medicine | 286 |
| Jacobio Pharmaceuticals Group | 207 |
Ascletis Pharma News
- 8 days ago - Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026 - PRNewsWire
- 12 days ago - Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes - PRNewsWire
- 15 days ago - Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity - PRNewsWire
- 21 days ago - Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity - PRNewsWire
- 5 weeks ago - Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 - PRNewsWire
- 6 weeks ago - Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis - PRNewsWire
- 2 months ago - Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - PRNewsWire
- 2 months ago - Ascletis Pharma Earnings release: H1 2026 - Filings